Inventiva (NASDAQ:IVA) Sees Strong Trading Volume – Still a Buy?

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) shares saw strong trading volume on Monday . 311,976 shares changed hands during trading, a decline of 45% from the previous session’s volume of 562,807 shares.The stock last traded at $3.91 and had previously closed at $3.91.

Wall Street Analysts Forecast Growth

IVA has been the subject of several research analyst reports. Truist Financial assumed coverage on Inventiva in a research note on Thursday, March 19th. They issued a “buy” rating and a $13.00 price objective for the company. Wall Street Zen cut Inventiva from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Inventiva in a report on Tuesday, April 21st. Three equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Inventiva currently has a consensus rating of “Buy” and an average target price of $16.56.

Inventiva Stock Performance

The firm has a 50 day moving average price of $4.52 and a 200-day moving average price of $5.32.

Institutional Investors Weigh In On Inventiva

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Creative Planning bought a new stake in Inventiva during the second quarter worth approximately $32,000. Commonwealth Equity Services LLC raised its position in shares of Inventiva by 19.6% in the fourth quarter. Commonwealth Equity Services LLC now owns 77,561 shares of the company’s stock valued at $361,000 after purchasing an additional 12,704 shares during the period. Virtu Financial LLC bought a new position in shares of Inventiva in the fourth quarter valued at approximately $60,000. XTX Topco Ltd acquired a new stake in shares of Inventiva in the fourth quarter worth $84,000. Finally, NewEdge Advisors LLC acquired a new stake in shares of Inventiva in the third quarter worth $116,000. 19.06% of the stock is currently owned by institutional investors and hedge funds.

Inventiva Company Profile

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.